Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,443	1,506	881.48	591.45	1,058	637.34
Short-Term Investments	375	120	0	0	1,075	440
Cash & Cash Equivalents	1,818	1,626	881.48	591.45	2,133	1,077
Cash Growth	55.70%	84.50%	49.04%	-72.27%	97.97%	30.65%
Receivables	707.1	705.79	651.49	563.36	396.49	355.99
Inventory	577.32	597.04	714.06	1,073	95.4	78.61
Other Current Assets	437.1	506.29	359.1	383.81	214.91	118.33
Total Current Assets	3,540	3,435	2,606	2,611	2,840	1,630
Property, Plant & Equipment	227.87	234.99	301.38	343.42	257.1	270.89
Goodwill and Intangibles	6,975	7,171	7,487	8,980	3,153	3,361
Other Long-Term Assets	584.31	551.78	440.64	363.95	285.88	276.74
Total Long-Term Assets	7,787	7,958	8,229	9,687	3,696	3,909
Total Assets	11,327	11,393	10,835	12,299	6,536	5,539
Accounts Payable	80.98	102.75	90.76	100.3	26.95	45.73
Deferred Revenue	0	0	0.46	2.56	4.86	9.58
Current Debt	605.38	604.95	31	31	246.32	33.39
Other Current Liabilities	875.86	828.99	810.97	675.45	375.62	275.79
Total Current Liabilities	1,562	1,537	933.19	809.3	653.75	364.49
Long-Term Debt	5,161	5,167	5,765	6,106	1,989	1,725
Other Long-Term Liabilities	907.14	952.46	1,051	1,418	233.86	338.33
Total Long-Term Liabilities	6,068	6,120	6,816	7,524	2,222	2,063
Total Liabilities	7,631	7,656	7,750	8,333	2,876	2,428
Total Debt	5,767	5,772	5,796	6,137	2,235	1,758
Debt Growth	-0.45%	-0.41%	-5.56%	174.61%	27.09%	10.15%
Retained Earnings	864.04	878.66	733.59	830.23	1,160	1,068
Comprehensive Income	-882.39	-842.15	-1,125.51	-400.36	-134.35	-223.39
Shareholders' Equity	3,696	3,737	3,086	3,965	3,660	3,111
Net Cash / Debt	-3,948.26	-4,145.86	-4,914.7	-5,545.7	-102.1	-681.14
Net Cash Per Share	-63.13	-57.53	-78.59	-92.90	-1.81	-11.84
Working Capital	1,978	1,899	1,673	1,802	2,186	1,266
Book Value Per Share	59.11	59.05	49.34	66.42	65.69	54.82

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).